葛藤提取物治疗绝经后骨质疏松的疗效观察

Observation on the therapeutic efficacy of Pueraria lobata extract in the treatment of postmenopausal osteoporosis

目的探讨葛藤提取物治疗绝经后骨质疏松的临床作用及临床疗效观察。方法选取2015年1月至2019年7月于莘县中医医院及日照市中医院门诊治疗的绝经后骨质疏松患者60例,随机分为观察组和对照组,对照组口服钙尔奇D,观察组在对照组基础上加服葛藤提取物,共治疗3个疗程。观察两组治疗后的血钙(Ca)、磷(P)、血清碱性磷酸酶(ALP)、血清雌二醇(E2)、降钙素(CT)、骨钙素(BGP)指标,腰背疼痛评分及中医证候积分来比较临床疗效,并进行安全性评价。结果治疗12周后,两组较治疗前均有明显的改善,观察组各指标与治疗前相比差异均有统计学意义(P<0.05),对照组仅ALP水平与治疗前相比差异有统计学意义(P<0.05);观察组与对照组相比,观察组Ca、P、BGP水平均高于对照组,ALP、E2、CT水平均低于对照组,差异有统计学意义(P<0.05)。观察组腰背疼痛评分及中医证候积分皆低于治疗前,差异有统计学意义(P<0.05),对照组仅腰背疼痛积分与治疗前相比差异有统计学意义(P<0.05);观察组与对照组相比腰背疼痛评分及中医证候积分皆低于对照组,差异有统计学意义(P<0.05)。观察组临床有效率高于对照组,差异有统计学意义(P<0.05)。安全性评价方面治疗组有1例,对照组有2例出现便秘症状,未发现2组患者有服用中药相关不良反应,无严重不良事件发生。结论采用葛藤提取物联合钙尔奇D治疗骨质疏松患者,在骨代谢、疼痛程度及中医症状等方面均有良好的改善作用,临床上值得推广使用。

Objective To investigate the clinical function and therapeutic efficacy of Pueraria lobata extract in the treatment of postmenopausal osteoporosis.Methods A total of 60 cases of postmenopausal osteoporosis patients treated in Traditional Chinese Medicine Hospital of Shen County and Traditional Chinese Medicine Hospital of Rizhao City from January 2015 to July 2019 were selected,and they were randomly divided into the observation group and the control group.The control group was treated with Caltrate D orally,while the observation group was treated with Pueraria lobata extract on the basis of the control group,all for three courses of treatment.After treatment,the indices of blood calcium(Ca),phosphorus(P),serum alkaline phosphatase(ALP),serum estradiol(E2),calcitonin(CT),osteocalcin(BGP),and the scores of lumbago and back pain and traditional Chinese medicine(TCM)syndrome were observed to compare the clinical efficacy and evaluate the safety.Results After 12 weeks of treatment,both groups were significantly improved compared with those before treatment.There were statistically significant differences in all indices of the observation group compared before and after treatment(P<0.05).There was statistically significant difference only in the ALP level of the control group compared before and after treatment(P<0.05).The levels of Ca,P and BGP in the observation group were all higher than those in the control group,while the levels of ALP,E2 and CT in the observation group were all lower than those in the control group,with statistically significant differences(P<0.05).The scores of lumbago and back pain and TCM syndrome in the observation group were all lower than those before treatment,with statistically significant differences(P<0.05).While there was statistically significant difference only in the scores of lumbago and back pain in the control group before and after treatment(P<0.05).The scores of lumbago and back pain and TCM syndrome in the observation group were all lower than those in the control group,with statistically significant differences(P<0.05).The clinical effective rate of the observation group was higher than that of the control group,with statistically significant difference(P<0.05).In terms of safety evaluation,there was 1 case of constipation symptom in the treatment group and 2 cases in the control group.There were no adverse reactions related to taking TCM and no serious adverse events occurred in the two groups.Conclusion The adoption of Pueraria lobata extract combined with Caltrate D calcium tablets in the treatment of osteoporosis patients has a good efficacy on improving bone metabolism,pain degree and symptoms of TCM,which is worthy of promotion and application in clinic.